APA (7th ed.) Citation

Tugnait, M., Gupta, N., Hanley, M. J., Sonnichsen, D., Kerstein, D., Dorer, D. J., . . . Narasimhan, N. (2020). Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Clinical pharmacology in drug development, 9(2), 214-223. https://doi.org/10.1002/cpdd.723

Chicago Style (17th ed.) Citation

Tugnait, Meera, Neeraj Gupta, Michael J. Hanley, Daryl Sonnichsen, David Kerstein, David J. Dorer, Karthik Venkatakrishnan, and Narayana Narasimhan. "Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers." Clinical Pharmacology in Drug Development 9, no. 2 (2020): 214-223. https://doi.org/10.1002/cpdd.723.

MLA (9th ed.) Citation

Tugnait, Meera, et al. "Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers." Clinical Pharmacology in Drug Development, vol. 9, no. 2, 2020, pp. 214-223, https://doi.org/10.1002/cpdd.723.